Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

Andrew J Hoover

Jared N Cumming

Amjad Ali

Kun Liu

Ping Liu

Thomas H Graham

Duane E DeMong

Umar Faruk Mansoor

Qiaolin Deng

Christopher W Plummer

Yonglian Zhang

Jianping Pan

Matthew A Larsen

Elisabeth Hennessy

Huijun Wang

Uma Swaminathan

Aaron Sather

Xiaoshen Ma

Duane Demong

Jared Cumming

Zahid Hussain

Yongxin Han

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, Rand Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2and/or A2receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2receptor and/or the adenosine A2receptor.

9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, Rand Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Growing community of inventors

Boston, MA, United States of America

Andrew J Hoover